Compare ALIT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | CDXS |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4M | 256.3M |
| IPO Year | 2020 | 2008 |
| Metric | ALIT | CDXS |
|---|---|---|
| Price | $0.79 | $2.51 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | ★ 21.3M | 1.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 21.33% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,000,000.00 | $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | $0.14 | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $0.48 | $0.96 |
| 52 Week High | $6.03 | $3.87 |
| Indicator | ALIT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 51.17 |
| Support Level | $0.65 | $2.40 |
| Resistance Level | $1.00 | $2.67 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 36.89 | 5.77 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.